Basson, Ashley James and McLaughlin, Mark G (2019) Functionalisation of Isoindolinones via a Calcium Catalysed Hosomi-Sakurai Allylation. Chemical Communications, 55. ISSN 1359-7345

Downloaded from: http://e-space.mmu.ac.uk/623167/
Publisher: Royal Society of Chemistry
DOI: https://doi.org/10.1039/c9cc02450f
Usage rights: Creative Commons: Attribution 3.0

Please cite the published version
This article can be cited before page numbers have been issued, to do this please use: A. J. Basson and M. G. McLaughlin, Chem. Commun., 2019, DOI: 10.1039/C9CC02450F.

This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
A rapid and functionally tolerant calcium catalysed Hosomi-Sakurai reaction has been realised. Employing 1 mol% calcium, allylated isoindolinones can be synthesised in high yields and the reaction is shown to be tolerant to a range of medicinally relevant functional groups including heterocycles. The synthetic utility of the reaction has been shown, and a plausible reaction mechanism is provided.

Isoindolinones are a common structural motif found in both drugs and natural products alike (Fig. 1). For example, Lenalidomide is used in the treatment of cancer,2 Taliscanine has been shown to have potential as treatment for neurological disorders,3 and zopiclone is an approved treatment for insomnia. Furthermore, investigational compounds such as A1 act as inhibitors of the MDM2-p53 protein-protein interaction.4

During the course of a medicinal chemistry program focused on the development of inhibitors against a metabolic disease target, we required ready access to a range of substituted γ-lactams bearing a functional group handle for further exploitation. Due to our groups’ burgeoning interesting in the use of calcium as a sustainable catalyst in synthesis,12 we decided to explore the use of 3-hydroxyisoindolinones as easily prepared precursors to N-acyliminium ions. We reasoned that through catalytic dehydration, these reactive intermediates could be produced and subsequently trapped by an allyl nucleophile.13 We started our investigation on model substrate 1a, employing a range of differing calcium catalysts and additive to effect the desired transformation (Table 1). We surveyed a range of calcium salts to determine the most appropriate source for the catalytic reaction, and saw no reaction with either CaCl₂ or Ca(OH)₂. Interestingly we saw a stoichiometric
reaction when Ca(OiPr)₂ was used, with yield increasing as loading increased.

Gratifyingly, when Ca(NTf₂)₂ was employed as a catalyst, we isolated 15% of the desired product after 1 hour. Addition of nBuNPF₆ further improved the yield, as did changing the solvent to 1,2-DCE. Further attempts at improving the reaction were not successful, including performing the reaction in a binary mix of solvents. To ensure the reaction required a calcium salt, we attempted the reaction using HNTf₂, however no reaction was observed. With these optimised conditions in hand, we probed the substrate scope of the reaction (Figure 4). As observed, both electron donating (2a,d) and electron withdrawing (2b,c) groups were well tolerated, each providing the allylated product in excellent yields and high efficiency.

We next moved our attention onto compound exhibiting a range of substitution patterns, with ortho (2e), meta (2f) and ortho/para (2g) substituents all tolerated well. As compounds of this class have been shown to exhibit a range of biological activities, we next turned our attention to heterocyclic moieties. As shown, the catalyst system is unaffected by traditionally difficult functional groups, with morpholine (2h), furan (2i), and thiophene (2j) all working well. Furthermore, acetal (2k) was also tolerated, affording the allylated product in high yield. All the examples shown thus far contained a free NH embedded within the lactam core. We therefore decided to investigate the effect of nitrogen substitution has on the reaction. We focused our attention on either easily removable groups (-Me, -Bn) or N-allyl group. As shown, these examples also worked well, efficiently providing the desired allylated product in high yields.

Our focus then turned to the use of branched allyl silanes, as these will produce compounds with increased levels of diversity (R₁ = Me or 4-BrPh). The reactions once again proceeded smoothly, affording the substituted γ-lactams good yield.

With the substrate scope completed, we next decided to investigate the synthetic applicability of our synthesised compounds. Employing Buchwald’s system for Suzuki cross couplings of aryl chlorides (2o), using commercial boronic acid 4, 5 was obtained in excellent yield.

Indolizidines are privileged scaffolds within medicinal chemistry and new routes towards these important scaffolds remains a priority. We reasoned that due to the high level of structural diversity achieved via this methodology, we could produce...
these important scaffolds easily and in high yields. Using \( \text{2p} \) as a model, we initially performed a ring closing metathesis with Grubb’s 1st generation catalyst.\(^{20}\) This proceeded well and in expected high yield. To further increase the utility, we performed the reaction in a one-pot fashion. Once again this produced the desired compound (\( \text{6} \)) in nearly identical yield to that observed with the isolated.

**Scheme 2. One Pot Synthesis of Indolizidines**

Finally, as the Hosomi-Sakurai reaction is traditionally non-catalytic,\(^{21}\) we wanted to perform preliminary studies to elucidate the potential mechanism of the reaction. The reaction proceeded slowly in the absence of \( \text{nBu}_4\text{NPf}_6 \), suggesting the crucial role the weakly coordinating \( \text{PF}_6^- \) ligand has. Furthermore, analysis of the crude reaction mixture by \(^1\text{H NMR} \) showed the presence of TMS-OH. Taken together, as well as inferring from previous studies,\(^{22}\) a plausible reaction mechanism is present below.

The active catalyst \( \text{A} \) is produced which reacts with the Lewis basic hydroxyl group. The resultant \( \text{N-acyliminium ion B} \) is produced, along with a postulated calcium alkoxy species \( \text{C} \). The \( \text{N-acyliminium ion} \) is then attacked by the allyl silane affording the stabilised cation \( \text{D} \). We then reason that due to the nucleophilic nature of the ligands in calcium complex \( \text{C} \), a facile elimination with concomitant reintroduction of \( \text{PF}_6^- \) occurs, providing the desired compound, releasing TMSOH and regenerating catalyst \( \text{A} \).

In summary, we have developed a facile and high yielding calcium catalysed Hosomi-Sakurai reaction. The reaction proceeds well, and is unencumbered by both steric and electronic factors. Furthermore, we have shown that both linear and branched silanes can react, providing much needed diversity of structure. Synthetic applicability has been demonstrated, and a plausible reaction mechanism proposed.

This work was supported by a Research Accelerator Grant from Manchester Metropolitan University. MML thanks MMU for startup funding. AJB thanks the Royal Society of Chemistry for an Undergraduate Research Bursary. We thank Liban Van Haren and Anthony Kromodimedjo for synthetic assistance.

**Conflicts of interest**

There are no conflicts to declare.

**Notes and references**

1. K. Speck and T. Magauer, *Beilstein J. Org. Chem.*, 2013, 9, 2048-2078.
2. X. Armoiry, G. Aulagner and T. Facon, *J. Clin. Phar. Ther.*, 2008, 33, 219-226.
3. H. A. Priestap, *Phytochemistry*, 1985, 24, 849-852.
4. I. R. Hardcastle, S. U. Ahmed, H. Atkins, G. Farnie, B. T. Golding, R. J. Griffin, S. Guyenne, C. Hutton, P. Källblad, S. J. Kemp, M. S. Kitching, D. R. Newell, S. Norbedo, J. S. Northen, R. J. Reid, K. Saravanan, H. M. G. Willems and J. Lunec, *J. Med. Chem.*, 2006, 49, 6209-6221.
5. (a) M.-D. Chen, X. Zhou, M.-Z. He, Y.-P. Ruan and P.-Q. Huang, *Tetrahedron*, 2004, 60, 1651-1657; (b) D. L. Comins, S. Schilling and Y. Zhang, *Org. Lett.*, 2005, 7, 95-98; (c) T. R. Belliotti, W. A. Brink, S. R. Kesten, J. R. Rubin, D. J. Wustrow, K. T. Zoski, S. Z. Whetzel, A. E. Corbin, T. A.
Pugsley, T. G. Heffner and L. D. Wise, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 1499-1502; (d) Y. Tian, J. Sun, K. Zhang, G. Li and F. Xu, *Synthesis*, 2018, **50**, 2255-2265; (e) D. Brahchmahi, A. K. Verma and S. Mehta, *J. Org. Chem.*, 2018, **83**, 3339-3347; (f) C. Alonso, M. González, F. Palacios and G. Rubiales, *J. Org. Chem.*, 2017, **82**, 6379-6387; (g) J. Maury, G. Force, B. Darses and D. Lebœuf, *Adv. Synth. Catal.*, 2018, **360**, 2752-2756.

6. (a) R. B. Bedford, J. G. Bowen and C. Méndez-Gálvez, *J. Org. Chem.*, 2012, **77**, 1719-1725; (b) H. S. P. Rao and A. V. B. Rao, *J. Org. Chem.*, 2015, **80**, 1506-1516; (c) S. R. Chemler, *Beilstein J. Org. Chem.*, 2015, **11**, 2252-2253.

7. (a) C. Zhang, Y. Ding, Y. Gao, S. Li and G. Li, *Org. Lett.*, 2018, **20**, 2595-2598; (b) W. Chen, L. Jin, Y. Zhu, X. Cao, L. Zheng and W. Mo, *Synlett*, 2013, **24**, 1856-1860.

8. Z.-Q. Wang, C.-G. Feng, M.-H. Xu and G.-Q. Lin, *J. Am. Chem. Soc.*, 2007, **129**, 5336-5337.

9. L. Shi, L. Hu, J. Wang, X. Cao and H. Gu, *Org. Lett.*, 2012, **14**, 1876-1879.

10. (a) S. Dhanasekaran, V. Bisai, R. A. Unhale, A. Suneja and V. K. Singh, *Org. Lett.*, 2014, **16**, 6068-6071; (b) S. Dhanasekaran, A. Suneja, V. Bisai and V. K. Singh, *Org. Lett.*, 2016, **18**, 634-637; (c) C. Qi, J. Gandon and D. Lebœuf, *Adv. Synth. Catal.*, 2017, **359**, 2671-2675.

11. D. D. Carolina, J. B. Eliezer and A. M. F. Carlos, *Mini-Rev. Med. Chem.*, 2007, **7**, 1108-1119.

12. H. J. Kiely-Collins, I. Sechi, P. E. Brennan and M. G. McLaughlin, *Chem. Commun.*, 2018, **54**, 654-657.

13. (a) C. Masusai, D. Soorukram, C. Kuhakarn, V. Reutrakul and M. Pohmakotr, *Eur. J. Org. Chem.*, 2018, **2018**, 160-169; (b) T. Bootwicha, D. Panichakul, C. Kuhakarn, S. Prabpai, P. Kongsaree, P. Tuchinda, V. Reutrakul and M. Pohmakotr, *J. Org. Chem.*, 2009, **74**, 3798-3805; (c) R. D. Dura, I. Modolo and L. A. Paquette, *Heterocycles*, 2007, **74**, 145; (d) I. Osante, E. Lete and N. Sotomayor, *Tetrahedron Lett.*, 2004, **45**, 1253-1256.

14. D. Lebœuf, M. Presset, B. Michelet, C. Bour, S. Bezenne-Lafolé and V. Gandon, *Chemistry – A European Journal*, 2015, **21**, 11001-11005.

15. (a) N. Meike and M. M. J., *Angew. Chem. Int. Ed.*, 2010, **49**, 3684-3687; (b) J. M. Begouin and M. Niggemann, *Chem. Eur. J.*, 2013, **19**, 8030-8041; (c) J.-M. Begouin, F. Capitta, X. Wu and M. Niggemann, *Org. Lett.*, 2013, **15**, 1370-1373; (d) L. Fu and M. Niggemann, *Chem. Eur. J.*, 2015, **21**, 6367-6370; (e) S. Gao, T. Stopka and M. Niggemann, *Org. Lett.*, 2015, **17**, 5080-5083; (f) V. J. Meyer, C. Ascheberg and M. Niggemann, *Chem. Eur. J.*, 2015, **21**, 6371-6374; (g) T. Stopka and M. Niggemann, *Org. Lett.*, 2015, **17**, 1437-1440; (h) V. J. Meyer and M. Niggemann, *Chem. Eur. J. Org. Chem.*, 2011, **2011**, 3671-3674.

16. J. Caruano, G. G. Muccioli and R. Robiette, *Org. Biomol. Chem.*, 2016, **14**, 10134-10156.

17. M. A. Düfert, K. L. Billingsley and S. L. Buchwald, *J. Am. Chem. Soc.*, 2013, **135**, 12877-12885.

18. J. P. Michael, *Nat. Prod. Rep.*, 2007, **24**, 191-222.

19. A. K. Maity and S. Roy, *J. Org. Chem.*, 2012, **77**, 2935-2941.

20. (a) P. Schwab, M. B. France, J. W. Ziller and R. H. Grubbs, *Angewandte Chemie International Edition in English*, 1995, **34**, 2039-2041; (b) P. Schwab, R. H. Grubbs and J. W. Ziller, *J. Am. Chem. Soc.*, 1996, **118**, 100-110.